The Vector Expedited Review Voucher (VERV) is a new incentive program to promote the discovery of novel insecticides in the fight against malaria and other mosquito-borne diseases.  VERV is administered by the US Environmental Protection Agency and is modeled after the US FDA’s successful Priority Review Voucher program.  On February 28, 2024 stakeholders and EPA representatives discussed the new program.  Jeffrey Moe, adjunct professor at the Duke Global Health Institute, and a co-author of the 2017 Health Affairs article which proposed VERV, opened the event by reflecting on FDA’s voucher program, “PRV had a positive impact on the development of treatments with limited profitability for neglected tropical diseases. The VERV program can, like PRV, stimulate the development of innovative vector control solutions to help us better control, and hopefully eradicate, diseases such as malaria.”

Photos, copies of presentation slides and a recording of the event are available on this site.